<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ALZAMEND NEURO RSS Feed | Nachrichten - www.finanzen.net</title><description>www.finanzen.net bietet Finanznachrichten zum weltweiten Börsengeschehen</description><category>Finanzen</category><link>https://www.finanzen.net</link><language>de-de</language><copyright>finanzen.net GmbH</copyright><lastBuildDate>Mon, 06 Apr 2026 08:53:03 +0200</lastBuildDate><atom:link href="https://www.finanzen.net/rss/alzamend%5Fneuro%2Drss%2Dfeed" rel="self" type="application/rss+xml"/><image><url>https://images.finanzen.net/images/finanzen_net_neu.gif</url><title>ALZAMEND NEURO RSS Feed | Nachrichten - www.finanzen.net</title><link>https://www.finanzen.net</link></image><item><title>Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital</title><pubDate>Wed, 19 Nov 2025 14:00:00 +0100</pubDate><link>https://www.finanzen.net/nachricht/aktien/alzamend-neuro-announces-completion-of-clinical-portion-of-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-conducted-at-massachusetts-general-hospital-15291667</link><description><![CDATA[<p><ul type="disc" xmlns="http://www.w3.org/1999/xhtml"><li><b><i>Topline data expected in first quarter of 2026</i></b></li><li><b><i>Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood  ...</p>]]></description><guid isPermaLink="true">https://www.finanzen.net/nachricht/aktien/alzamend-neuro-announces-completion-of-clinical-portion-of-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-conducted-at-massachusetts-general-hospital-15291667</guid></item></channel></rss>
